Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

Little is known about the long-term efficacy inhaled corticosteroids in chronic obstructive pulmonary disease (COPD). We investigated the efficacy of inhaled budesonide on decline in lung function and respiratory symptoms in a 3-year placebo-controlled study of patients with COPD. We used a parallel...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 1999-05, Vol.353 (9167), p.1819-1823
Main Authors: Vestbo, Jøorgen, Søorensen, Torben, Lange, Peter, Brix, Anders, Torre, Piero, Viskum, Kaj
Format: Article
Language:English
Subjects:
Administration, Inhalation
Administration, Topical
Adult
Anti-Inflammatory Agents - administration & dosage
Anti-Inflammatory Agents - therapeutic use
Biological and medical sciences
Budesonide - administration & dosage
Budesonide - therapeutic use
Cardiovascular disease
Chronic obstructive pulmonary disease
Clinical trials
Corticoids
Double-Blind Method
Drugs
Female
Follow-Up Studies
Forced Expiratory Volume - physiology
Glucocorticoids
Humans
Lung Diseases, Obstructive - drug therapy
Lung Diseases, Obstructive - physiopathology
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Respiratory function
Respiratory system
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Little is known about the long-term efficacy inhaled corticosteroids in chronic obstructive pulmonary disease (COPD). We investigated the efficacy of inhaled budesonide on decline in lung function and respiratory symptoms in a 3-year placebo-controlled study of patients with COPD. We used a parallel-group, randomised, double-blind, placebo-controlled design in a single-centre study, nested in a continuing epidemiological survey (the Copenhagen City Heart Study). Inclusion criteria were as follows: no asthma; a ratio of forced expiratory volume in 1 s (FEV 1) and vital capacity of 0·7 or less; FEV 1 which showed no response (
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(98)10019-3